
Overview
Dr. Ross C. Donehower is an oncologist in the Baltimore area, caring for patients with gastrointestinal cancers. He was part of the team that developed premedications that allowed paclitaxel — a chemotherapy medication now used to treat several types of cancers — to be safely given to patients. The Virginia and D.K. Ludwig Professor in Clinical Investigation of Cancer, he serves as the director of the Hematology & Medical Oncology Fellowship Program and director of the Division of Medical Oncology at the Johns Hopkins School of Medicine. Dr. Donehower received his undergraduate degree from Hamline University and earned his M.D. from the University of Minnesota. He completed his residency at The Johns Hopkins Hospital. Dr. Donehower joined the Johns Hopkins faculty in 1980. Prior to joining Johns Hopkins, Dr. Donehower was a surgeon with the U.S. Public Health Service and a clinical associate of the medicine branch and clinical pharmacology branch at the National Cancer Institute. His research interests include gastrointestinal cancers, new anticancer drug development and pharmacology. Dr. Donehower serves on the editorial boards of numerous scholarly journals, including the International Journal of Oncology. He has been recognized by the American Society of Clinical Oncology with a 2017 Excellence in Teaching Award. He is a member of several professional organizations, including the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research.
Dr. Donehower is rated as an Experienced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Colorectal Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.
His clinical research consists of co-authoring 36 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
10803 Falls Road, Pavilion III STE 1500, Pavilion III STE 1500, Lutherville, MD 21093
201 North Broadway Street, Viragh BLDG 5th FL, Baltimore, MD 21287
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Skip Viragh Outpatient Cancer Center
Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Elite provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.
Skip Viragh Outpatient Cancer Center
Dr. Mark Yarchoan is a physician–scientist based in Baltimore who specializes in the treatment and study of gastrointestinal cancers, with a particular focus on liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). He received his undergraduate degree from Amherst College and his medical degree from the Perelman School of Medicine at the University of Pennsylvania. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, followed by a fellowship in medical oncology at the Johns Hopkins University School of Medicine, where he joined the faculty in 2018. Dr. Yarchoan leads a research laboratory dedicated to developing novel immunotherapies for liver cancers. His translational research program integrates analyses of clinical trial biospecimens with preclinical modeling to identify and overcome barriers to effective antitumor immunity. A major focus of his work is the development of therapeutic cancer vaccines for hepatobiliary malignancies. He serves as Principal Investigator on multiple clinical trials for hepatobiliary cancers, contributes to international guideline committees for liver cancer, and is a member of the Johns Hopkins Graduate Training Programs in Cellular and Molecular Medicine and Immunology. Dr. Yarchoan’s contributions have been recognized with numerous honors, including the ASCO Young Investigator Award, the Conquer Cancer Foundation Career Development Award, the Mark R. Clements Award from the Cholangiocarcinoma Foundation, and the Blue Faery Award for Excellence in Liver Cancer Research. Dr. Yarchoan is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Pancreatic Cancer, and Hepatectomy.
Skip Viragh Outpatient Cancer Center
Marina Baretti, MD, is an assistant professor at Johns Hopkins University School of Medicine and the Jiasheng Chair in Hepato-Biliary Cancer Research. She also serves as Co-Director of the Liver and Biliary Cancer Multidisciplinary Clinic at the Sidney Kimmel Comprehensive Cancer Center (SKCCC). Dr. Baretti received her medical degree from the University of Pisa in Italy. She completed her internal medicine residency and oncology fellowship at University of Milan. She then went on and completed her Postdoctoral and Medical Oncology Fellowship at Johns Hopkins University, Baltimore, Maryland. She is deeply engaged in bridging the gap between laboratory discoveries and clinical application, working closely with laboratory-based scientists to accelerate the development of novel therapeutic strategies. Her academic research is centered on the development of novel agents in hepatobiliary cancers, with particular interest in combinatorial approaches of immunotherapies. She is currently the principal investigator on multiple clinical trials in FLC, HCC and cholangiocarcinoma at Johns Hopkins University, collaborating closely with laboratory-based researchers to move laboratory findings into patients. Through her work, Dr. Baretti strives to improve outcomes for patients with rare GI cancers by identifying innovative therapies that are informed by a deeper understanding of tumor biology and the tumor microenvironment. Dr. Baretti was the recipient of the 2018 American Society of Clinical Oncology Young Investigator Award. Dr. Baretti was also awarded with the 2020 Career Development Award for the MD Anderson Cancer Center’s pancreatic cancer NCI Specialized Programs of Research Excellence (SPORE). Dr. Baretti is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, and Pancreatic Cancer.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Colorectal CancerDr. Donehower isDistinguished. Learn about Colorectal Cancer.
- Familial Colorectal CancerDr. Donehower isDistinguished. Learn about Familial Colorectal Cancer.
- Neuroendocrine TumorDr. Donehower isDistinguished. Learn about Neuroendocrine Tumor.
- Advanced
- Familial Pancreatic CancerDr. Donehower isAdvanced. Learn about Familial Pancreatic Cancer.
- Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
- Lynch SyndromeDr. Donehower isAdvanced. Learn about Lynch Syndrome.
- Pancreatic CancerDr. Donehower isAdvanced. Learn about Pancreatic Cancer.
- PancreaticoduodenectomyDr. Donehower isAdvanced. Learn about Pancreaticoduodenectomy.
- Experienced
- Ampullary CancerDr. Donehower isExperienced. Learn about Ampullary Cancer.
- Anal CancerDr. Donehower isExperienced. Learn about Anal Cancer.
- Appendix CancerDr. Donehower isExperienced. Learn about Appendix Cancer.
- Cholangiocarcinoma (Bile Duct Cancer)Dr. Donehower isExperienced. Learn about Cholangiocarcinoma (Bile Duct Cancer).
- Fibrolamellar CarcinomaDr. Donehower isExperienced. Learn about Fibrolamellar Carcinoma.
- Gallbladder AdenocarcinomaDr. Donehower isExperienced. Learn about Gallbladder Adenocarcinoma.


